We had the great pleasure to meet with Jessica Ailani (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the use of gepants and their impact on the treatment landscape for migraines.
The abstract entitled: ‘Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine‘ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- Could you give us a brief overview of the new generation of gepants and their impact on the treatment landscape for migraines? (0:18)
- How does the efficacy and safety of gepants compare with antibody-based calcitonin gene-related peptide (CGRP) antagonists? (1:57)
- What are the advantages of atogepant and what have we learned about its efficacy and safety to date? (4:26)
Disclosures: Jessica Ailani has been an independent consulting (received honoraria) for Amgen, Abbvie, Biohaven, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Teva, Impel, Satsuma, Axsome, Vorso, Aeon, Theranica, Medscape; and has ownership of Stocks in CtrM; and is on part of the Speakers Bureau, and received honoraria for promotional speaking from Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva; and has provided editorial services (Honoraria) to Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, Infomedica (AHS Virtual Highlights 2020), SELF (medical reviewer). Jessica Ailani has also received Clinical Trial grants from (Fees to Institution) American Migraine Foundation, Allergan/Abbvie, Biohaven, Eli Lilly and Company, Satsuma and Zosano.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Robert Music, The Migraine Trust: Improving migraine care – ensuring patient-focussed diagnosis and treatment in the UK
“Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges around diagnosis, care and access to the right treatment. ” – Rob Music, CEO, The […]
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!